Molecular Targeting Technologies

Molecular Targeting Technologies: New Radiotherapeutic Is Effective and Less Toxic for Neuroendocrine Tumor Patients

WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) announced an article entitled “Peptide Receptor Radionuclide Therapy (PRRT) of Late-Stage Neuroendocrine Tumor (NETs) Patients with Multiple Cycles of  Lu-DOTA-EB-TATE” just …

Molecular Targeting Technologies: New Radiotherapeutic Is Effective and Less Toxic for Neuroendocrine Tumor Patients Read More